自1896年創立至今,羅氏一直尋求更好的方法預防、診斷和治療疾病,持續為社會帶來貢獻。

— 相關資訊 —

詞彙表

生物製劑(Biological medicine)(亦稱生物製藥學藥品、生物技術藥品或生物治療藥品產品):生物製劑產品的活動物質是一種生物物質,生物物質是一種從生物來源中提取的物質。物理-化學生物測試的組合,它的生產過程及控制是對描繪它的特性及決定它的品質所必需的。

活性物質(Active substance):一種特定藥品中的活性成分或分子,提供此藥品的治療性質,或避免一種或數種特定疾病的性質。

不良反應(Adverse effect):任何在使用給予藥品後發生的非故意或不利的事件。是與醫療管理相關的傷害,對比於疾病的併發症。醫療管理 包括所有方面的照顧,包括診斷及治療、診斷或治療失敗,以及提供照顧的系統 與設備。不良反應或許可以避免或無可避免。

抗體(Antibody):抗體(亦稱為免疫球蛋白,縮寫為Ig)是在血液或其他體液中找到的大蛋白質。抗體是免疫 系統用於辨認及中和外來物 體,例如細菌及病毒。

化學藥品 / 藥物(Chemical medicine/drug)(亦稱小分子藥品):生產時沒有生命有機體參與的一種藥品,這些包括具有明確結構及特性的化 學複合物。

療效(Efficacy):一種藥物或藥品,在人類上使用時,產生希望得到的治療效果的能力。

參考資料

  1. Hospital Authority Smart Patient Website. Patient Participation for Successful Drug Treatment. Available at: http://www21.ha.org.hk/smartpatient/SmartElders/static/migration/files/mini_site/smartelder/pdf/drugknowledge/04.pdf (Accessed on 30 Nov 2017).
  2. Hospital Authority Smart Patient Website. Patient Handbook. Available at: http://www21.ha.org.hk/smartpatient/SPW/MediaLibraries/SPW/SPWMedia/2017_%E9%86%92%E7%9B%AE%E7%97%85%E4%BA%BA%E6%89%8B%E5%86%8A.pdf (Accessed on 30 Nov 2017).
  3. Hospital Authority Smart Patient Website. Self Management Tips. Available at: http://smartpatient.elearningpro.com:8887/smartpatient/SPW/zh-hk/Self-Care-Tips/Health-Management/Self-Management-Tips/ (Accessed on 30 Nov 2017).
  4. UK Department of Health. Liberating the NHS: No decision about me, without me. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216980/Liberating-the-NHS-No-decision-about-me-without-me-Government-response.pdf (Accessed on 30 Nov 2017).
  5. Mellstedt, H., et al. The challenge of biosimilars. Annals of Oncology: of cial journal of the European Society for Medical Oncology / ESMO 19, 411–9 (2008) 6. Mellstedt, H., Niederwieser, D. & Ludwig, H. The challenge of biosimilars. Annals of Oncology: of cial journal of the European Society for Medical Oncology / ESMO 19, 411–9 (2008)
  6. Hong Kong Cancer Fund. Palliative Care Information. Available at: http://cancer-fund.org/upload/booklets/file/Talking%20to%20Pdf%202015C.pdf (Accessed on 30 Nov 2017).
  7. Hong Kong Patients’ Voices. Briefing Paper on Biological and Biosimilar Medicines. Available at: http://www.hkpv.org/uploads/files/2016/education/02_Dragon_IAPO%20Briefing%20Paper-HKTC.pdf (Accessed on 30 Nov 2017).
  8. FDA. Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.pdf (Accessed on 30 Nov 2017).
  9. Regulatory Affairs Professionals Society. Demystifying CMC Regulatory Strategy for Biologics, 2012
To Top